

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																																
NATURE OF CONVEYANCE:	SECURITY AGREEMENT																																
CONVEYING PARTY DATA																																	
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; text-align: center; padding: 5px;">Name</td> <td style="width: 30%; text-align: center; padding: 5px;">Execution Date</td> </tr> <tr> <td style="padding: 5px;">GTC Biotherapeutics, Inc.</td> <td style="padding: 5px;">12/19/2008</td> </tr> </table>	Name	Execution Date	GTC Biotherapeutics, Inc.	12/19/2008																													
Name	Execution Date																																
GTC Biotherapeutics, Inc.	12/19/2008																																
RECEIVING PARTY DATA																																	
Name:	LFB Biotechnologies S.A.S.U.																																
Street Address:	3, Avenue des Tropiques, LES ULIS																																
City:	Courtaboeuf																																
State/Country:	FRANCE																																
Postal Code:	91940																																
PROPERTY NUMBERS Total: 32																																	
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%; text-align: center; padding: 5px;">Property Type</th> <th style="text-align: center; padding: 5px;">Number</th> </tr> </thead> <tbody> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">09571116</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">11061295</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">11058458</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">09028551</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">11355557</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">08170579</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">08410887</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">09012904</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">11060041</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">10933854</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">10423792</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">09333213</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">10081400</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">09175684</td></tr> <tr><td style="padding: 5px;">Application Number:</td><td style="padding: 5px;">10082018</td></tr> </tbody> </table>	Property Type	Number	Application Number:	09571116	Application Number:	11061295	Application Number:	11058458	Application Number:	09028551	Application Number:	11355557	Application Number:	08170579	Application Number:	08410887	Application Number:	09012904	Application Number:	11060041	Application Number:	10933854	Application Number:	10423792	Application Number:	09333213	Application Number:	10081400	Application Number:	09175684	Application Number:	10082018	
Property Type	Number																																
Application Number:	09571116																																
Application Number:	11061295																																
Application Number:	11058458																																
Application Number:	09028551																																
Application Number:	11355557																																
Application Number:	08170579																																
Application Number:	08410887																																
Application Number:	09012904																																
Application Number:	11060041																																
Application Number:	10933854																																
Application Number:	10423792																																
Application Number:	09333213																																
Application Number:	10081400																																
Application Number:	09175684																																
Application Number:	10082018																																

OP \$1280.00 09571116

500738353

PATENT
REEL: 022019 FRAME: 0205

Application Number:	11140676
Application Number:	12050569
Application Number:	11007852
Application Number:	09175683
Application Number:	10949975
Application Number:	10835836
Application Number:	11586431
Application Number:	11051216
Application Number:	08391743
Application Number:	09143155
Application Number:	11284585
Application Number:	11788775
Application Number:	08648235
Application Number:	09550001
Application Number:	09490657
Application Number:	08282256
Application Number:	09298971

CORRESPONDENCE DATA

Fax Number: (617)542-2241
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 617-542-6000
 Email: grdenningham@mintz.com
 Correspondent Name: Carol H. Peters
 Address Line 1: One Financial Center
 Address Line 2: Mintz Levin
 Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	34948-002
NAME OF SUBMITTER:	Carol H. Peters

Total Attachments: 35

source=LFB-GTC Financing Patent and License Security Agreement#page1.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page2.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page3.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page4.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page5.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page6.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page7.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page8.tif
 source=LFB-GTC Financing Patent and License Security Agreement#page9.tif

source=LFB-GTC Financing Patent and License Security Agreement#page10.tif
source=LFB-GTC Financing Patent and License Security Agreement#page11.tif
source=LFB-GTC Financing Patent and License Security Agreement#page12.tif
source=LFB-GTC Financing Patent and License Security Agreement#page13.tif
source=LFB-GTC Financing Patent and License Security Agreement#page14.tif
source=LFB-GTC Financing Patent and License Security Agreement#page15.tif
source=LFB-GTC Financing Patent and License Security Agreement#page16.tif
source=LFB-GTC Financing Patent and License Security Agreement#page17.tif
source=LFB-GTC Financing Patent and License Security Agreement#page18.tif
source=LFB-GTC Financing Patent and License Security Agreement#page19.tif
source=LFB-GTC Financing Patent and License Security Agreement#page20.tif
source=LFB-GTC Financing Patent and License Security Agreement#page21.tif
source=LFB-GTC Financing Patent and License Security Agreement#page22.tif
source=LFB-GTC Financing Patent and License Security Agreement#page23.tif
source=LFB-GTC Financing Patent and License Security Agreement#page24.tif
source=LFB-GTC Financing Patent and License Security Agreement#page25.tif
source=LFB-GTC Financing Patent and License Security Agreement#page26.tif
source=LFB-GTC Financing Patent and License Security Agreement#page27.tif
source=LFB-GTC Financing Patent and License Security Agreement#page28.tif
source=LFB-GTC Financing Patent and License Security Agreement#page29.tif
source=LFB-GTC Financing Patent and License Security Agreement#page30.tif
source=LFB-GTC Financing Patent and License Security Agreement#page31.tif
source=LFB-GTC Financing Patent and License Security Agreement#page32.tif
source=LFB-GTC Financing Patent and License Security Agreement#page33.tif
source=LFB-GTC Financing Patent and License Security Agreement#page34.tif
source=LFB-GTC Financing Patent and License Security Agreement#page35.tif

PATENT AND LICENSE SECURITY AGREEMENT

This PATENT AND LICENSE SECURITY AGREEMENT (this "Agreement"), dated as of December 22, 2008, is by and between GTC BIOTHERAPEUTICS, INC. ("Grantor") and LFB BIOTECHNOLOGIES S.A.S.U. ("Grantee").

W I T N E S S E T H:

WHEREAS, pursuant to that certain Note and Warrant Purchase Agreement by and between the Grantor and the Grantee dated October 31, 2008 (the "Purchase Agreement"), the Grantor is issuing and selling to the Grantee a secured convertible note in the original principal amount of \$15,000,000 (the "Convertible Note") and a warrant to purchase up to 23,193,548 shares of common stock of the Grantor;

WHEREAS, in connection with the Purchase Agreement and Convertible Note Grantor and Grantee have entered into that certain Security Agreement, dated as of the date hereof (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"); and

WHEREAS, Grantor has agreed to pledge the Patent Collateral (as defined below) to Grantee in accordance with the terms of the Security Agreement and this Agreement, to secure the Indebtedness (as defined in the Security Agreement).

NOW, THEREFORE, in consideration of these premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. Defined Terms.

(i) Unless otherwise defined herein, capitalized terms used herein which are defined in the Security Agreement shall have the meanings specified in the Security Agreement.

(ii) The words "hereof", "herein", and "hereunder" and words of like import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section and schedule references are to this Agreement unless otherwise specified.

(iii) All terms defined in this Agreement in the singular shall have comparable meanings when used in the plural, and vice versa, unless otherwise specified.

(iv) "Default" means the occurrence of either of the following events: (a) any default by Grantor under the terms of the Security Agreement or any other Debt Document; or (b) any Event of Default.

2. Security Interest in Patents. As security for prompt payment in full of all of the Indebtedness, Grantor hereby grants to Grantee a first priority security interest, having priority over all other security interests in all of Grantor's now owned or existing and hereafter acquired or arising (collectively, the "Patent Collateral");

(i) patents and patent applications, and the inventions and improvements described and claimed therein, including, without limitation, those patents and patent applications listed on Schedule A, and (a) the reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, (b) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements thereof, and (c) the right to sue for past, present and future infringements thereof (all of the foregoing patents and applications, together with the items described in the foregoing clauses (a)-(c), being sometimes hereinafter individually and/or alone or in conjunction with the non-U.S. Patents identified in Schedule C collectively referred to as the "Patents");

(ii) license agreements with any other party in connection with any Patents or such other party's patents or patent applications, whether Grantor is a licensor or licensee under any such license agreement, including, but not limited to, the license agreements listed on Schedule B, and the right upon the occurrence and during the continuance of a Default to use the foregoing in connection with the enforcement of the rights of Grantee under the Security Agreement (all of the foregoing being hereinafter referred to collectively as the "Licenses"). Notwithstanding the foregoing provisions of this Section 2, the Licenses shall not include any license agreement which by its terms prohibits (which prohibition is enforceable under applicable law) the grant of the security interest contemplated by this Agreement for so long as such prohibition continues; it being understood that upon request of Grantee, Grantor will in good faith use reasonable efforts to obtain consent for the creation of a security interest in favor of Grantee in Grantor's rights under such license agreement; and

(iii) Non-U.S. Patents and Licenses, including without limitation those listed on Schedule C,

3. Restrictions on Future Agreements. Grantor will not, without Grantee's prior written consent, enter into any agreement, including, without limitation, any license agreement, which is inconsistent with this Agreement, and Grantor further agrees that it will not take any action, and will not permit any action to be taken by others subject to its control, including licensees, or fail to take any action, which would affect the validity or enforcement of the rights transferred to Grantee, under this Agreement or any other Debt Document or the rights associated with those Patents which are necessary or desirable in the operation of Grantor's business.

4. New Patents. Grantor represents and warrants that the Patents and Licenses listed on Schedules A, B and C, collectively include all of the patents, patent applications now owned by Grantor, and all license agreements in force as of the date hereof with any other party in connection with any Patents or such other party's patents or patent applications, whether Grantor is a licensor or licensee under any such license agreement. If, prior to the termination of this Agreement, Grantor shall (i) obtain rights to any new patentable inventions or license agreements or any patents or patent applications in connection therewith or (ii) become entitled to the benefit of any patent, patent application or any reissue, division, continuation, renewal, extension or continuation-in-part related to any Patent or any improvement on any Patent, the provisions of Section 2 shall automatically apply thereto, and Grantor shall give to Grantee prompt written

notice thereof. Grantor hereby authorizes Grantee to modify this Agreement by (a) amending Schedules A, B or C, as the case may be, to include any future patents, patent applications and license agreements in connection with patents and patent applications that are Patents or Licenses under Section 2 or under this Section 4, and (b) filing, in addition to and not in substitution for, this Agreement, a short form of this Agreement containing on Schedules A, B or C thereto, as the case may be, such future patents, patent applications and license agreements which are Patents or Licenses, as the case may be, under Section 2 or this Section 4. Notwithstanding the foregoing, Grantor agrees that Grantee's security interest shall extend to all of the collateral listed in Section 2 and this Section 4, regardless of whether Grantee actually amends Schedules A, B or C, respectively.

5. Royalties. Grantor hereby agrees that the use by Grantee of the Patents and Licenses as authorized hereunder shall be coextensive with Grantor's rights thereunder and with respect thereto and without any liability for royalties or other related charges from Grantee to Grantor.

6. Nature and Continuation of Grantee's Security Interest. This Agreement is made for collateral security purposes only. This Agreement shall create a continuing security interest in the Patents and the Licenses and shall remain in full force and effect until the Indebtedness has been paid in full and the Security Agreement terminated, at such time the rights granted to Grantee hereunder shall also terminate.

7. Further Assignments and Security Interests. Grantor agrees not to sell or assign its respective interests in, or grant any license under (other than granting any license in the ordinary course of business), the Patents without the prior written consent of Grantee.

8. Duties of Grantor. Grantor shall have the duty to the extent desirable in the conduct of Grantor's business and consistent with Grantor's current business practices or Grantor's reasonable business judgment: (i) to prosecute diligently any patent application that is part of the Patents pending as of the date hereof or thereafter until the termination of this Agreement; (ii) to make application on such unpatented but patentable inventions as Grantor deems appropriate; (iii) to take reasonable steps to preserve and maintain all of Grantor's rights in the patent applications and patents that are part of the Patents and (iv) obtain any consents, waivers or agreements necessary to enable Grantee to exercise its remedies with respect to any and all Patent Collateral. Any expenses incurred in connection with the foregoing shall be borne by Grantor. Grantor shall not abandon any right to file a patent application or any pending patent application or patent which is or shall be in the Grantor's reasonable business judgment necessary or economically desirable to the operation of Grantor's business. Grantee shall have no duty with respect to the Patents and Licenses. Without limiting the generality of the foregoing, Grantee shall not be under any obligation to take any steps necessary to preserve rights in the Patents or Licenses against any other parties, but may do so at its option during the continuance of a Default, and all expenses incurred in connection therewith shall be for the sole account of Grantor and added to the Indebtedness secured thereby.

9. Grantee's Right to Sue; Limited License. From and after the occurrence and during the continuance of a Default, Grantee shall have the right, but shall not be obligated, upon prior written notice to Grantor, to bring suit to enforce the Patents and the Licenses, and, if

Grantee shall commence any such suit, Grantor shall, at the request of Grantee, do any and all lawful acts and execute any and all proper documents required by Grantee in aid of such enforcement. Grantor shall, upon demand, promptly reimburse and indemnify Grantee for all reasonable costs and expenses incurred by Grantee in the exercise of its rights under this Section 9 in accordance with Section 11 hereof and Section 7(e) of the Security Agreement (including, without limitation, all reasonable attorneys' fees). If, for any reason whatsoever, Grantee is not reimbursed with respect to the costs and expenses referred to in the preceding sentence, such costs and expenses shall be added to the Indebtedness secured hereby. Grantor hereby grants to Grantee a license with respect to all Patents and Licenses owned or used by Grantor to the extent necessary to enable Grantee, effective upon the occurrence of any Default, to realize on the Patents and Licenses and any successor or assign to enjoy the benefits of the Patents and Licenses. This license shall inure to the benefit of Grantee and its successors, assigns and transferees, whether by voluntary conveyance, operation of law, assignment, transfer, foreclosure, deed in lieu of foreclosure or otherwise. Such license is granted free of charge, without requirement that any monetary payment whatsoever including, without limitation, any royalty or license fee, be made to any Grantor or any other Person by Grantee or any other Person.

10. Waivers. No course of dealing between Grantor and Grantee, and no failure to exercise or delay in exercising on the part of Grantee any right, power or privilege hereunder or under the Security Agreement or other Debt Documents shall operate as a waiver of any of Grantee's rights, powers or privileges. No single or partial exercise of any right, power or privilege hereunder or under the Security Agreement or other Debt Documents shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

11. Grantee's Exercise of Rights and Remedies Upon Default. Notwithstanding anything set forth herein to the contrary, it is hereby expressly agreed that upon the occurrence and during the continuance of a Default, Grantee may exercise any of the rights and remedies provided in this Agreement or any of the other Debt Documents. Without limiting the generality of the foregoing, Grantor acknowledges and agrees that (i) the Patents and Licenses comprise a portion of the Collateral and Grantee shall have the right to exercise its rights under the Security Agreement with respect to the Patents and Licenses to the same extent as with respect to all other items of Collateral described therein, and (ii) from and after the occurrence and during the continuation of a Default, Grantee or its nominee may use the Patents and Licenses to assemble, manufacture, sell, prepare for sale or take possession of the Collateral, or for any other purpose in connection with the conduct of Grantor's business. Any proceeds of any of the Patent Collateral may be applied by the Grantee to the payment of expenses in connection with the enforcement of Grantee's rights and remedies hereunder and in connection with the Patent Collateral, including, without limitation, reasonable attorneys' fees and legal expenses, and any balance of such proceeds may be applied by Grantee toward the payment of such of the Indebtedness, and in such order of application, as Grantee may from time to time elect (and, after payment in full of all Indebtedness, any excess shall be delivered to Grantor or as a court of competent jurisdiction shall direct).

12. Severability. If any provision hereof is held to be illegal or unenforceable, such provision shall be fully severable, and the remaining provisions hereof shall remain in full force and effect and shall not be affected by such provision's severance. Furthermore, in lieu of any

such provision, there shall be added automatically as a part of this Agreement a legal and enforceable provision as similar in terms to the severed provision as may be possible.

13. Modification. This Agreement cannot be altered, amended or modified in any way, except as specifically provided in Sections 2 and 4 hereof or by a writing signed by the parties hereto.

14. Cumulative Remedies; Power of Attorney. All of Grantee's rights and remedies with respect to the Patents and the Licenses, whether established hereby, by any other agreements or by law, shall be cumulative and may be exercised singularly or concurrently. Grantor hereby irrevocably appoints Grantee as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor or otherwise to carry out the acts described below. Upon the occurrence and during the continuance of a Default, Grantor hereby authorizes Grantee to, in its sole discretion, (i) endorse Grantor's name on all applications, documents, papers and instruments necessary or desirable for Grantee in the use of the Patents and the Licenses, (ii) take any other actions with respect to the Patents and the Licenses as Grantee deems is in its best interest, (iii) grant or issue any exclusive or non-exclusive license with respect to the Patents to anyone on commercially reasonable terms, and (iv) assign, pledge, convey or otherwise transfer title in or dispose of the Patents and the Licenses to anyone on commercially reasonable terms. Grantor hereby ratifies all that such attorney-in-fact shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and shall be irrevocable until this Agreement shall have been terminated pursuant to Section 6 hereof. Grantor acknowledges and agrees that this Agreement is not intended to limit or restrict in any way the rights and remedies of Grantee under the Security Agreement or other Debt Documents, but rather is intended to facilitate the exercise of such rights and remedies. Grantee shall have, in addition to all other rights and remedies given it by the terms of this Agreement, all rights and remedies allowed by law and the rights and remedies of a Grantee under the Uniform Commercial Code as enacted in any jurisdiction in which, respectively, either (x) the Patents may be located or deemed located or (y) the Licenses were granted.

15. Binding Effect; Benefits. This Agreement shall be binding upon Grantor and its successors and assigns, and shall inure to the benefit of Grantee and its nominees, successors and assigns. The successors and assigns of Grantor shall include, without limitation, a receiver, trustee or Grantor-in-possession of or for Grantor; provided, however, that Grantor shall not voluntarily assign its obligations hereunder without the prior written consent of Grantee.

16. **CHOICE OF LAW; WAIVER OF JURY TRIAL; SERVICE OF PROCESS.** THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. GRANTOR AND GRANTEE HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. GRANTOR HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO SERVICE OF PROCESS BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED. IN NO EVENT WILL GRANTEE BE LIABLE FOR LOST PROFITS OR OTHER SPECIAL OR CONSEQUENTIAL DAMAGES.

17. Notices. Except as otherwise herein provided, any notice or other communication required hereunder shall be in writing (messages sent by e-mail or other electronic transmission (other than by telecopier) shall not constitute a writing, however any signature on a document or other writing that is transmitted by e-mail or telecopier shall constitute a valid signature for purposes hereof), and shall be deemed to have been validly served, given or delivered when received by the recipient if hand delivered, sent by commercial overnight courier or sent by facsimile, or three (3) Business Days after deposit in the United States mail, with proper first-class postage prepaid and addressed to the party at its address and/or facsimile number set forth in the Security Agreement, or to such other address as either party shall specify to the other in writing from time to time.

18. Section Headings. The Section headings herein are for convenience of reference only, and shall not affect in any way the interpretation of any of the provisions hereof.

19. Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of this Agreement by telefacsimile shall be equally as effective as delivery of a manually executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by telefacsimile or electronic transmission shall also deliver a manually executed counterpart of this Agreement, but the failure to deliver a manually executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement.

20. Right of Recordal of Security Interest. Grantee shall have the right, but not the obligation, at the expense of Grantor, to record this Agreement in the United States Patent and Trademark Office and with such other United States and foreign recording authorities deemed reasonable and proper by Grantee. Grantee shall advise Grantor of such recordals and Grantor shall comply with all formalities and execute all documents deemed reasonable and proper by Grantee in connection therewith. Upon satisfaction in full of the Indebtedness and termination of the Security Agreement, Grantor shall have the right to effect recordal of such satisfaction or termination at the expense of Grantor in the United States Patent and Trademark Office and with such other United States and foreign recording authorities deemed reasonable and proper by Grantor, and Grantee shall execute all documents deemed reasonable and proper by Grantor in connection therewith. Grantee and Grantor shall cooperate to effect all such recordals hereunder. Grantor shall reimburse Grantee for all reasonable expenses (including, without limitation, filing fees, translation fees, fee related to retention of local patent clerks and local attorneys) incurred by Grantee relating to such recordals within fifteen (15) days of making such reimbursement request and providing documentation evidencing such expenses to Grantor.

21. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the liens and security interest granted to Grantee pursuant to this Agreement and the exercise of any right or remedy by Grantee hereunder are subject to the provisions of that certain Subordination and Intercreditor Agreement dated as of December __, 2008 (the "Intercreditor Agreement") by and among Grantor, Grantee and General Electric Capital Corporation, a Delaware corporation. In the event of any conflict between the terms of the Intercreditor Agreement and this Agreement, the terms of the Intercreditor Agreement shall govern and control.

[SIGNATURE PAGE FOLLOWS]

Signature Page to Patent and License Security Agreement

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement on the day and year first above written.

GRANTOR:


GTC BIOTHERAPEUTICS, INC., a
Massachusetts corporation

By: John B. Green
Name: John B. Green
Title: Senior Vice President, Chief Financial
Officer and Treasurer

Signature Page to Patent and License Security Agreement

GRANTEE:

LFB BIOTECHNOLOGIES S.A.S.U., a
société anonyme established under the laws
of France

By:  _____

Name: Christian Béchon

Title: President Directeur General

SCHEDULE A
TO PATENT AND LICENSE SECURITY AGREEMENT

U.S. PATENTS AND U.S. PATENT APPLICATIONS

See attached listing.

BOS 645006.1

GTC OWNED PATENTS AND PATENT APPLICATIONS

Docket No.	GTC Ref.	Title	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Ownership
G0744.70000US01	GTC-35	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	09/571116	12-May-2000					GTC
G0744.70002US00	GTC-234 CIP	A METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION	11/061295	18-Feb-2005	US-2006-0188439-A1	24-Aug-2006			GTC and Mayo Foundation for Medical Education and Research
G0744.70019US00	GTC-233	AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF	11/058458	15-Feb-2005	US-2006-0182744-A1	17-Aug-2006			GTC and Mayo Foundation for Medical Education and Research
G0744.70010US00	GTC-11 CPA	TRANSGENICALLY PRODUCED NON-SECRETED PROTEINS	09/028551	24-Feb-1998			6528699	04-Mar-2003	GTC
G0744.70012US00	GTC-240	CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION	11/355557	16-Feb-2006	US-2007-0192878-A1	16-Aug-2007			GTC
G0744.70014US00	GTC-1	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	08/170579	20-Dec-1993			5827690	27-Oct-1998	GTC
G0744.70014US01	GTC-ID	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	08/410887	27-Mar-1995			5849992	15-Dec-1998	GTC
G0744.70014US02	GTC-001 D3	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	09/012904	23-Jan-1998	US-2004-0006776-A1	08-Jan-2004			GTC
G0744.70015US02	GTC-211C	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	11/060041	17-Feb-2005	US-2005-0208000-A1	22-Sep-2005			GTC
G0744.70017US01	GTC-220	METHOD FOR THE PRODUCTION OF FUSION PROTEINS IN TRANSGENIC MAMMAL MILK	10/933854	03-Sep-2004	US-2006-0105347-A1	18-May-2006			GTC
G0744.70021US03	GTC-34D	TRANSGENIC AND CLONED MAMMALS	10/423792	25-Apr-2003	US-2003-0177513-A1	18-Sep-2003			GTC
G0744.70030US01	GTC-6	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	09/333213	15-Jun-1999			6548653	15-Apr-2003	GTC
G0744.70030US02	GTC-6 D	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	10/081400	20-Feb-2002	US-2002-0155998-A1	24-Oct-2002	7101971	05-Sep-2006	GTC
G0744.70031US02	GTC-39	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	09/175684	20-Oct-1998			6593463	15-Jul-2003	GTC

G0744.70031US03	GTC-39C	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	10/082018	20-Feb-2002	US-2002-0144299-A1	03-Oct-2002	GTC
G0744.70031US04	GTC-39 D	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	11/140676	27-May-2005	US-2005-0235371-A1	20-Oct-2005	GTC
G0744.70034US02	GTC-222	ERYTHROPOIETIN ANALOG-IGG FUSION PROTEINS	12/050569	18-Mar-2008		8-Apr-08	GTC
G0744.70036US00	GTC-229	METHOD OF PURIFYING RECOMBINANT MSP 1-42 DERIVED FROM PLASMODIUM FALCIPARUM	11/007852	09-Dec-2004	US-2006-0130159-A1	15-Jun-2006	GTC
G0744.70037US02	GTC-40	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	09/175683	20-Oct-1998			GTC
G0744.70037US03	GTC-40C	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	10/949975	24-Sep-2004	US-2005-0071890-A1	31-Mar-2005	GTC
G0744.70040US00	GTC-226	METHOD OF USING RECOMBINANT HUMAN ANTITHROMBIN FOR NEUROCOGNITIVE DISORDERS	10/835836	30-Apr-2004	US-2005-0245444-A1	03-Nov-2005	GTC
G0744.70045US01	GTC-238	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	11/586431	23-Oct-2006	US-2008-0118501-A1	22-May-08	GTC and Genzyme
G0744.70046US01	GTC-225 01	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	11/051216	04-Feb-2005	US-2005-0197496-A1	08-Sep-2005	GTC
G0744.70047US00	GTC-10	TRANSGENICALLY PRODUCED ANTITHROMBIN III	08/391743	21-Feb-1995		5843705	GTC
G0744.70047US01	GTC-10C	TRANSGENICALLY PRODUCED ANTITHROMBIN III	09/143155	28-Aug-1998		6441145	GTC
G0744.70047US03	GTC-10C3	TRANSGENICALLY PRODUCED ANTITHROMBIN III	11/284585	14-Nov-2005	US-2008-0176786-A1	24-Jul-08	GTC

G0744.70051US01	GTC-243	METHODS AND PRODUCTS RELATED TO THE TRANSFER OF MOLECULES FROM BLOOD TO THE MAMMARY GLAND	11/788775	20-Apr-2007	US-2008- 0063780-A1	13-Mar-08	GTC
G0744.70058US00	GTC-13	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	08/648235	13-May-1996			GTC
G0744.70059US01	GTC-30	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	09/550001	14-Apr-2000			GTC
G0744.70063US02	GTC-14D	TRANSGENICALLY PRODUCED PROLACTIN	09/490637	24-Jan-2000	6545198	08-Apr-2003	GTC
G0744.70079US00	GTC-52	PROCESS FOR STERILE FILTRATION OF MILK	08/282256	29-Jul-1994	5576040	19-Nov-1996	GTC
G0744.70081US00	GTC-33C	METHODS OF RECONSTRUCTED GOAT EMBRYO TRANSFER	09/298971	23-Apr-1999	6588017	17-Jun-2003	GTC

**SCHEDULE B
TO PATENT AND LICENSE SECURITY AGREEMENT**

LICENSES

See attached listing.

BOS 645006.1

GTC LICENSED PATENTS & APPLICATIONS

Docket No.	GTC Ref.	Title	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Ownership
G0744.70025US00	GTC-210	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	10/300233	19-Nov-2002	US-2004-0097710-A1	20-May-2004	7087719	08-Aug-2006	Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70025US01	GTC-210D	METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	11/378727	17-Mar-2006	US-2006-0178309-A1	10-Aug-2006			Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70032US01	GTC-2	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	08/376620	23-Jan-1995			5756687	26-May-1998	Genzyme
G0744.70033US01	GTC-38C	PRODUCTION OF CFTR IN THE MILK OF TRANSGENIC MICE	08/088416	07-Jul-1993			6448469	10-Sep-2002	Genzyme
G0744.70033US02	GTC-38C2	THE PRODUCTION OF MEMBRANE PROTEINS IN THE MILK OF TRANSGENIC MAMMALS	09/627290	28-Jul-2000			6472584	29-Oct-2002	Genzyme
G0744.70033US03	GTC-38C.3	PRODUCTION OF CFTR IN THE MILK OF TRANSGENIC MICE	10/185269	27-Jun-2002	US-2003-0033618-A1	13-Feb-2003	6743966	01-Jun-2004	Genzyme
G0744.70038US01	GTC-62	TREATMENT OF LUNG DISORDERS	10/396855	25-Mar-2003	US-2004-0192595-A1	30-Sep-2004			Board of Regents, The University of Texas System
G0744.70039US01	GTC-224	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	11/057522	14-Feb-2005	US-2005-0192226-A1	01-Sep-2005			Board of Regents, The University of Texas System
G0744.70042US03	GTC-3C2	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	07/938322	31-Aug-1992			7045676	16-May-2006	Genzyme
G0744.70042US07	GTC-3 D3	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	07/839194	20-Feb-1992					Genzyme
G0744.70042US08	GTC-3 C3	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	08/246259	19-May-1994			6727405	27-Apr-2004	Genzyme and US Dept. of HHS
G0744.70045US01	GTC-238	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	11/586431	23-Oct-2006	US-2008-0118501-A1	22-May-08			GTC and Genzyme
G0744.70049US02	GTC-241	TREATMENT AND PROPHYLAXIS WITH 4-1BB-BINDING AGENTS	12/269462						Mayo Foundation for Medical Education and Research
G0744.70050US01	GTC-242	ENHANCEMENT OF IMMUNE RESPONSES BY 4-1BB-BINDING AGENTS	10/492056	17-Aug-2004	US-2005-0013811-A1	20-Jan-2005			Mayo Foundation for Medical Education and Research

**SCHEDULE C
TO PATENT AND LICENSE SECURITY AGREEMENT**

NON-U.S. PATENTS

See attached listing.

BOS 645006.1

GTC CONTROLLED PATENTS & APPLICATIONS

Docket No.	GTC Ref.	Title	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Ownership
G0744.70000AU00	GTC-35 AU	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	50083/00	12-May-2000			782069	13-Oct-2005	GTC
G0744.70000CA00	GTC-35 CA	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	2368608	12-May-2000					GTC
G0744.70000DE00	GTC-35 DE	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000EP00	GTC-35 EP	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000ES00	GTC-35 ES	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000FR00	GTC-35 FR	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000GB00	GTC-35 GB	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000IE00	GTC-35 IE	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000IT00	GTC-35 IT	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	932348.6	12-May-2000	EP1194033	10-Apr-2002	1194033	19-Dec-2007	GTC
G0744.70000US01	GTC-35	TRANSGENICALLY PRODUCED ANTITHROMBIN III AND MUTANTS THEREOF	09/571116	12-May-2000					GTC
G0744.70001AU00	GTC-36 AU	METHODS OF PRODUCING CLONED AND TRANSGENIC MAMMALS	14928/01	27-Sep-2000			783143	12-Jan-2006	GTC
G0744.70001NZ00	GTC-36 NZ	METHODS OF PRODUCING CLONED AND TRANSGENIC MAMMALS	517930	27-Sep-2000			517930	10-May-2004	GTC
G0744.70002EP00	GTC-234 EP	A METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION	5723386.8	18-Feb-2005	1850872	07-Nov-2007			GTC and Mayo Foundation for Medical Education and Research

G0744.70002US00	GTC-234 CIP	A METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION	11/061295	18-Feb-2005	US-2006-0188439-A1	24-Aug-2006	GTC and Mayo Foundation for Medical Education and Research
G0744.70003IL00	GTC-43 IL	METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND PURIFICATION OF THE TARGET MOLECULE	149003	16-Oct-2000			GTC
G0744.70003JP00	GTC-43 JP	METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND PURIFICATION OF THE TARGET MOLECULE	2001-529255	16-Oct-2000			GTC
G0744.70003KR00	GTC-43 KR	METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND PURIFICATION OF THE TARGET MOLECULE	10-2002-7004804	16-Oct-2000	772465	26-Oct-2007	GTC
G0744.70003MX00	GTC-43 MX	METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND PURIFICATION OF THE TARGET MOLECULE	PA/a/2002/003702	16-Oct-2000	01-Sep-2002		GTC
G0744.70003NZ00	GTC-43 NZ	METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND PURIFICATION OF THE TARGET MOLECULE	518263	16-Oct-2000	1497	26-Mar-2004	GTC
G0744.70004NZ00	GTC-31 NZ	TRANSGENICALLY PRODUCED PLATELET DERIVED GROWTH FACTOR	523220	19-Jun-2001	1509	24-Mar-2005	GTC
G0744.70007NZ00	GTC-55 NZ	PURIFICATION OF HUMAN SERUM ALBUMIN	529767	13-Jun-2002		09-Feb-2006	Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70008AU00	GTC-208 AU	METHOD FOR THE RAPID SELECTION OF HOMOZYGOUS PRIMARY CELL LINES FOR THE PRODUCTION OF TRANSGENIC ANIMALS BY SOMATIC CELL NUCLEAR TRANSFER	2003249049	14-Jul-2003			GTC

G0744.70008IL00	GTC-208 IL	METHOD FOR THE RAPID SELECTION OF HOMOZYGOUS PRIMARY CELL LINES FOR THE PRODUCTION OF TRANSGENIC ANIMALS BY SOMATIC CELL NUCLEAR TRANSFER	167547	14-Jul-2003				GTC
G0744.70008NZ01	GTC-208 NZ	A METHOD FOR THE RAPID SELECTION OF HOMOZYGOUS PRIMARY CELL LINES FOR THE PRODUCTION OF TRANSGENIC ANIMALS BY SOMATIC CELL NUCLEAR TRANSFER	566810	14-Jul-2003				GTC
G0744.70010AU01	GTC-11D AU	TRANSGENICALLY PRODUCED NON- SECRETED PROTEINS	40611/02	24-Feb-1998	27-Jun-2002	783753	23-Mar-2006	GTC
G0744.70010US00	GTC-11 CPA	TRANSGENICALLY PRODUCED NON- SECRETED PROTEINS	09/028551	24-Feb-1998		6528699	04-Mar-2003	GTC
G0744.70011CN00	GTC-200 CN	METHOD AND SYSTEM FOR FUSION AND ACTIVATION FOLLOWING NUCLEAR TRANSFER IN RECONSTRUCTED EMBRYOS	03802084.X	08-Jan-2003	CN1615356A	27-May-2005	07-Feb-2007	GTC
G0744.70011NZ00	GTC-200 NZ	METHOD AND SYSTEM FOR FUSION AND ACTIVATION FOLLOWING NUCLEAR TRANSFER IN RECONSTRUCTED EMBRYOS	533692	08-Jan-2003	1527	29-Sep-2006	11-Jan-2007	GTC
G0744.70012CA00	GTC-240 CA	CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION		08-Mar-2006				GTC
G0744.70012EP00	GTC-240 EP	CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION	6737391	08-Mar-2006	1991063	19-Nov-2008		GTC
G0744.70012NZ00	GTC-240 NZ	CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION	571253	08-Mar-2006				GTC
G0744.70012US00	GTC-240	CLARIFICATION OF TRANSGENIC MILK USING DEPTH FILTRATION	11/355557	16-Feb-2006	US-2007- 0192878-A1	16-Aug-2007		GTC
G0744.70014AU00	GTC-1 AU	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	1517295	20-Dec-1994	19-Mar-1998	688845	02-Jul-1998	GTC
G0744.70014AU03	GTC-1D3 AU	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	2003248473	20-Dec-1994	2003248473	2003248473	23-Aug-2007	GTC
G0744.70014AU04	GTC-1D4 AU	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	2007205719	20-Dec-1994				GTC
G0744.70014AT00	GTC-1 AT	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	12-Nov-2003	GTC
G0744.70014BE00	GTC-1 BE	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	12-Nov-2003	GTC

G0744.70014DK00	GTC-1 DK	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014EP00	GTC-1 EP	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014FR00	GTC-1 FR	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014DE00	GTC-1 DE	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	69433325	12-Nov-2003	GTC
G0744.70014GR00	GTC-1 GR	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014IE00	GTC-1 IE	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014IT00	GTC-1 IT	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014JP00	GTC-1 JP	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	517602/1995	20-Dec-1994		05-Sep-2007	3970923	15-Jun-2007	GTC
G0744.70014L00	GTC-1 LI	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014LU00	GTC-1 LU	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014MC00	GTC-1 MC	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014NL00	GTC-1 NL	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014NZ00	GTC-1 NZ	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	278744	20-Dec-1994			278744	20-Dec-1994	GTC
G0744.70014PT00	GTC-1 PT	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014ES00	GTC-1 ES	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014SE00	GTC-1 SE	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014CH00	GTC-1 CH	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014GB00	GTC-1 GB	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	95906691.1	20-Dec-1994	EP0741515	29-Jun-1995	741515	12-Nov-2003	GTC
G0744.70014US00	GTC-1	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	08/170579	20-Dec-1993			5827690	27-Oct-1998	GTC
G0744.70014US01	GTC-1D	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	08/410887	27-Mar-1995			5849992	15-Dec-1998	GTC
G0744.70014US02	GTC-001 D3	TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK	09/012904	23-Jan-1998	US-2004-0006776-A1	08-Jan-2004			GTC
G0744.70015AU00	GTC-211 AU	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	3238700	22-Feb-2000		10-Apr-2003	759261	31-Jul-2003	GTC
G0744.70015CA00	GTC-211 CA	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	2362565	22-Feb-2000					GTC

G0744.70015EP00	GTC-211 EP	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	910265.8	22-Feb-2000	EP1162934	19-Dec-2001	GTC
G0744.70015JP00	GTC-211 JP	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	2000-600667	22-Feb-2000			GTC
G0744.70015US02	GTC-211C	COMPOSITIONS AND METHODS FOR PREVENTION OF PHOTOAGING	11/060041	17-Feb-2005	US-2005-0208000-A1	22-Sep-2005	GTC
G0744.70017IL00	GTC-220 IL	METHOD FOR THE PRODUCTION OF FUSION PROTEINS IN TRANSGENIC MAMMAL MILK	174011	03-Sep-2004			GTC
G0744.70017NZ00	GTC-220 NZ	METHOD FOR THE PRODUCTION OF FUSION PROTEINS IN TRANSGENIC MAMMAL MILK	546144	03-Sep-2004			GTC
G0744.70017US01	GTC-220	METHOD FOR THE PRODUCTION OF FUSION PROTEINS IN TRANSGENIC MAMMAL MILK	10/933854	03-Sep-2004	US-2006-0105347-A1	18-May-2006	GTC
G0744.70018AU00	GTC-42 AU	TRANSGENICALLY PRODUCED FUSION PROTEINS	200138832	18-Sep-2000		17-Apr-2001	GTC and United States of America, as represented by the Secretary of Health and Human Services and AstraZeneca
G0744.70018NZ00	GTC-42 NZ	TRANSGENICALLY PRODUCED FUSION PROTEINS	517666	18-Sep-2000		08-Jun-2004	GTC and United States of America, as represented by the Secretary of Health and Human Services and AstraZeneca
G0744.70018SG00	GTC-42 SG	TRANSGENICALLY PRODUCED FUSION PROTEINS	200201429-8	18-Sep-2000		31-Mar-2004	GTC and United States of America, as represented by the Secretary of Health and Human Services and AstraZeneca
G0744.70019EP00	GTC-233 EP	AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF	5723079.9	15-Feb-2005	1851244	07-Nov-2007	GTC and Mayo Foundation for Medical Education and Research
G0744.70019US00	GTC-233	AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF	11/058458	15-Feb-2005	US-2006-0182744-A1	17-Aug-2006	GTC and Mayo Foundation for Medical Education and Research

G0744.70020EP00	GTC-203 EP	METHOD FOR SELECTING CELL LINES TO BE USED FOR NUCLEAR TRANSFER IN MAMMALIAN SPECIES	3723815.1	25-Mar-2003	EP1490487	29-Dec-2004	GTC
G0744.70020JP00	GTC-203 JP	METHOD FOR SELECTING CELL LINES TO BE USED FOR NUCLEAR TRANSFER IN MAMMALIAN SPECIES	2003-582284	25-Mar-2003			GTC
G0744.70020NZ00	GTC-203 NZ	METHOD FOR SELECTING CELL LINES TO BE USED FOR NUCLEAR TRANSFER IN MAMMALIAN SPECIES	535367	25-Mar-2003	535367	15-May-08	GTC
G0744.70021AU01	GTC-34D AU	TRANSGENIC AND CLONED MAMMALS	2003204830	02-Nov-1999	2003204830	30-Aug-2007	GTC
G0744.70021AU03	GTC-34 AU	TRANSGENIC AND CLONED MAMMALS	2008202456	02-Nov-1999			Trustees of Tufts College
G0744.70021CA00	T001461	TRANSGENIC AND CLONED MAMMALS	2350233	02-Nov-1999			Trustees of Tufts College
G0744.70021CA01	GTC-34D CA	TRANSGENIC AND CLONED MAMMALS	2431859	02-Nov-1999	2431859	21-Feb-2006	GTC
G0744.70021CA02	GTC-34D2 CA	TRANSGENIC AND CLONED MAMMALS	2525148	02-Nov-1999			GTC
G0744.70021EP00	T001461	TRANSGENIC AND CLONED MAMMALS	99971451.2	02-Nov-1999	EP1127113	29-Aug-2001	Trustees of Tufts College
G0744.70021EP01	GTC-34D EP	TRANSGENIC AND CLONED MAMMALS	3014030.5	02-Nov-1999	EP1375654	02-Jan-2004	GTC
G0744.70021JP00	T001461	TRANSGENIC AND CLONED MAMMALS	2000-579729	02-Nov-1999			Trustees of Tufts College
G0744.70021JP01	GTC-34D JP	TRANSGENIC AND CLONED MAMMALS	2003-182181	02-Nov-1999		18-Jan-08	GTC
G0744.70021US03	GTC-34D	TRANSGENIC AND CLONED MAMMALS	10423792	25-Apr-2003	US-2003-0177513-A1	18-Sep-2003	GTC
G0744.70022JP00	GTC-221 JP	USE OF AEROSOLIZED ANTIHROMBIN TO TREAT ACUTE LUNG INJURY	2006-551170	14-Jan-2005			Board of Regents, The University of Texas System
G0744.70025AU00	GTC-210 AU	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	2003285055	28-Oct-2003			Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70025CA00	GTC-210 CA	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	2506594	28-Oct-2003			Taurus hSA LLC (joint venture of GTC and Fresenius)

G0744.70025CN00	GTC-210 CN	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	200380107863.90	28-Oct-2003	CN1732185A	08-Feb-2006	Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70025IL00	GTC-210 IL	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	168670	28-Oct-2003			Taurus hSA LLC (joint venture of GTC and Fresenius)
G0744.70025NZ00	GTC-210 NZ	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	540149	28-Oct-2003	1547	30-May-08	11-Sep-08
G0744.70025US00	GTC-210	A METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	10/300233	19-Nov-2002	US-2004-0097710-A1	20-May-2004	08-Aug-2006
G0744.70025US01	GTC-210D	METHOD FOR THE CRYSTALLIZATION OF HUMAN SERUM ALBUMIN	11/378727	17-Mar-2006	US-2006-0178309-A1	10-Aug-2006	
G0744.70028AU00	GTC-56 AU	ISOLATION OF IMMUNOGLOBULIN MOLECULES THAT LACK INTER-HEAVY CHAIN DISULFIDE BONDS	2003267135	11-Sep-2003			GTC
G0744.70028CN00	GTC-56 CN	ISOLATION OF IMMUNOGLOBULIN MOLECULES THAT LACK INTER-HEAVY CHAIN DISULFIDE BONDS	3825024.1	11-Sep-2003	CN1856324A	01-Nov-2006	GTC
G0744.70028IL00	GTC-56 IL	ISOLATION OF IMMUNOGLOBULIN MOLECULES THAT LACK INTER-HEAVY CHAIN DISULFIDE BONDS	167455	11-Sep-2003			GTC
G0744.70028JP00	GTC-56 JP	ISOLATION OF IMMUNOGLOBULIN MOLECULES THAT LACK INTER-HEAVY CHAIN DISULFIDE BONDS	2004-537770	11-Sep-2003			GTC
G0744.70028NZ00	GTC-56 NZ	ISOLATION OF IMMUNOGLOBULIN MOLECULES THAT LACK INTER-HEAVY CHAIN DISULFIDE BONDS	538894	11-Sep-2003			GTC
G0744.70030AU00	GTC-6 AU	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	45668/99	15-Jun-1999	775422	05-Jan-2000	18-Nov-2004
G0744.70030AT00	GTC-6 AT	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006
G0744.70030BE00	GTC-6 BE	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006
G0744.70030DK00	GTC-6 HK	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006
G0744.70030EP00	GTC-6 EP	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006
G0744.70030FR00	GTC-6 FR	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006
G0744.70030DE00	GTC-6 DE	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	13-Sep-2006

G0744.70030GR00	GTC-6 GR	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	20060404139	13-Sep-2006	GTC
G0744.70030HK00	GTC-6 HK	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	1105360	15-Jun-1999	1036475	04-Jan-2002	HK1036475	04-May-2007	GTC
G0744.70030IE00	GTC-6 IE	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030IT00	GTC-6 IT	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	354277BE/2006	13-Sep-2006	GTC
G0744.70030JP00	GTC-6 JP	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	2000-554863	15-Jun-1999			4087563	29-Feb-08	GTC
G0744.70030LI00	GTC-6 LI	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030NL00	GTC-6 NL	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030ES00	GTC-6 ES	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030CH00	GTC-6 CH	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030GB00	GTC-6 GB	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	99928656	15-Jun-1999	1088084	04-Apr-2001	1088084	13-Sep-2006	GTC
G0744.70030US01	GTC-6	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	09/333213	15-Jun-1999			6548653	15-Apr-2003	GTC
G0744.70030US02	GTC-6 D	ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION	10/081400	20-Feb-2002	US-2002- 0155998-A1	24-Oct-2002	7101971	05-Sep-2006	GTC
G0744.70031AP00	GTC-39 AP	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	AP/P/2000/001813	20-Oct-1998			AP1219	22-Oct-2003	GTC
G0744.70031OA00	GTC-39 OAPI	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	1200000112	20-Oct-1998			11520	13-Aug-2001	GTC
G0744.70031AU00	GTC-39 AU	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	1108899	20-Oct-1998			760231	21-Aug-2003	GTC
G0744.70031AU01	GTC-39 AUD	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	2003200911	20-Oct-1998	2003200911	08-Jun-2006	2003200911	21-Sep-2006	GTC

G0744.70031BR00	GTC-39 BR	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	P19813110-9	20-Oct-1998	1545	15-Aug-2000	GTC
G0744.70031CN00	GTC-39 CN	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	98810398.2	20-Oct-1998	CN1276834A	13-Dec-2000	GTC
G0744.70031ID00	GTC-39 ID	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	W-20000731	20-Oct-1998	25.072	07-Sep-2000	GTC
G0744.70031JP00	GTC-39 JP	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	2000-517094	20-Oct-1998			GTC
G0744.70031MX00	GTC-39 MX	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	P/A/2000/3840	20-Oct-1998		261985	GTC
G0744.70031US02	GTC-39	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	09/175684	20-Oct-1998		6593463	GTC
G0744.70031US03	GTC-39C	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	10/082018	20-Feb-2002	US-2002-0144299-A1	03-Oct-2002	GTC
G0744.70031US04	GTC-39 D	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	11/140676	27-May-2005	US-2005-0235371-A1	20-Oct-2005	GTC
G0744.70032AU00	GTC-2 AU	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	6268394	17-Feb-1994		693436	Genzyme
G0744.70032AT00	GTC-2 AT	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	05-Nov-1997	Genzyme
G0744.70032BE00	GTC-2 BE	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	05-Nov-1997	Genzyme

G0744.70032CA00	GTC-2CA	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	2157118	17-Feb-1994		2157118	26-Jun-2007	Genzyme
G0744.70032DK00	GTC-2 DK	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032EP00	GTC-2 EP	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032FR00	GTC-2 FR	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032DE00	GTC-2 DE	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	69424687.5-08	24-May-2000	Genzyme
G0744.70032GR00	GTC-2 GR	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032IE00	GTC-2 IE	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032IT00	GTC-2 IT	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032JP00	GTC-2 JP	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	519999/1994	17-Feb-1994		3801196	12-May-2006	Genzyme
G0744.70032LI00	GTC-2 LI	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032LU00	GTC-2 LU	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032MC00	GTC-2 MC	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032NL00	GTC-2 NL	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032PT00	GTC-2 PT	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032ES00	GTC-2 ES	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032SE00	GTC-2 SE	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032CH00	GTC-2 CH	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032GB00	GTC-2 GB	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	94910120.8	17-Feb-1994	EP0804070	804070	24-May-2000	Genzyme
G0744.70032US01	GTC-2	ISOLATION OF COMPONENTS OF INTEREST FROM MILK	08/376620	23-Jan-1995		5756687	26-May-1998	Genzyme
G0744.70033US01	GTC-38C	PRODUCTION OF CFTR IN THE MILK OF TRANSGENIC MICE	08/088416	07-Jul-1993		6448469	10-Sep-2002	Genzyme
G0744.70033US02	GTC-38C2	THE PRODUCTION OF MEMBRANE PROTEINS IN THE MILK OF TRANSGENIC MAMMALS	09/627290	28-Jul-2000		6472584	29-Oct-2002	Genzyme
G0744.70033US03	GTC-38C 3	PRODUCTION OF CFTR IN THE MILK OF TRANSGENIC MICE	10/185269	27-Jun-2002	US-2003-0033618-A1	6743966	01-Jun-2004	Genzyme

G0744.70034US02	GTC-222	ERYTHROPOIETIN ANALOG-IGG FUSION PROTEINS	12/050569	18-Mar-2008			GTC
G0744.70036US00	GTC-229	METHOD OF PURIFYING RECOMBINANT MSP 1-42 DERIVED FROM PLASMODIUM FALCIPARUM	11/007852	09-Dec-2004	US-2006-0130159-A1	15-Jun-2006	GTC
G0744.70037AP00	GTC-40 AP	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	AP/P/2000/001812	20-Oct-1998		27-Nov-2006 AP 1678	GTC
G0744.70037OA00	GTC-40 OA	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	1200000111	20-Oct-1998		11372	GTC
G0744.70037AJ01	GTC-40 AJD	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	2003200914	20-Oct-1998	200300914	01-Feb-2007 2003200914	GTC
G0744.70037BR00	GTC-40 BR	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	P19812945-7	20-Oct-1998	1544	08-Aug-2000	GTC
G0744.70037CA00	GTC-40 CA	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	2306799	20-Oct-1998			GTC
G0744.70037CN00	GTC-40 CN	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	ZL98810400.8	20-Oct-1998	CN1276831A	13-Dec-2000 ZL98810400.8	GTC
G0744.70037CN01	GTC-40 CN	MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	200710104933.50	20-Oct-1998	CN101134966 A	5-Mar-08	GTC
G0744.70037EP01	GTC-40 EPD	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	40222373.7	20-Oct-1998	EP1555319	20-Jul-2005	GTC

G0744.70037ID00	GTC-40 ID	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	W-200000730	20-Oct-1998		ID00015271	20-Jan-2005	GTC
G0744.70037MX00	GTC-40 MX	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	00 3839	20-Oct-1998		01-Mar-2001		GTC
G0744.70037US02	GTC-40	NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	09/175683	20-Oct-1998				GTC
G0744.70037US03	GTC-40C	NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS	10/949975	24-Sep-2004	US-2005-0071890-A1	31-Mar-2005		GTC
G0744.70038AU00	GTC-62 AU	TREATMENT OF LUNG DISORDER	2003233428	25-Mar-2003	2003233428	31-Jul-08	13-Nov-08	Board of Regents, The University of Texas System
G0744.70038CA00	GTC-62 CA	TREATMENT OF LUNG DISORDER	2480790	25-Mar-2003				Board of Regents, The University of Texas System
G0744.70038CN00	GTC-62 CN	TREATMENT OF LUNG DISORDER	03807463.X	25-Mar-2003	CN1774258A	17-May-2006	30-Apr-08	Board of Regents, The University of Texas System
G0744.70038EP00	GTC-62 EP	TREATMENT OF LUNG DISORDER	3728277.9	25-Mar-2003	EP1494696	11-Jan-2005		Board of Regents, The University of Texas System
G0744.70038IL00	GTC-62 IL	TREATMENT OF LUNG DISORDER	164078	25-Mar-2003				Board of Regents, The University of Texas System
G0744.70038JP00	GTC-62 JP	TREATMENT OF LUNG DISORDER	2003-581716	25-Mar-2003				Board of Regents, The University of Texas System
G0744.70038KR00	GTC-62 KR	TREATMENT OF LUNG DISORDER	10-2004-7015636	25-Mar-2003				Board of Regents, The University of Texas System
G0744.70038NZ00	GTC-62 NZ	TREATMENT OF LUNG DISORDER	535487	25-Mar-2003				Board of Regents, The University of Texas System

G0744.70038NZ01	GTC-62 NZ	TREATMENT OF LUNG DISORDER	570403	25-Mar-2003		Board of Regents, The University of Texas System
G0744.70038US01	GTC-62	TREATMENT OF LUNG DISORDERS	10396855	25-Mar-2003	US-2004-0192595-A1	Board of Regents, The University of Texas System
G0744.70039AU00	GTC-224 AU	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	2005216044	15-Feb-2005		Board of Regents, The University of Texas System
G0744.70039CA00	GTC-224 CA	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	2557411	15-Feb-2005		Board of Regents, The University of Texas System
G0744.70039EP00	GTC-224 EP	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	5713495.9	15-Feb-2005	1725244	Board of Regents, The University of Texas System
G0744.70039IL00	GTC-224 IL	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	177588	15-Feb-2005		Board of Regents, The University of Texas System
G0744.70039JP00	GTC-224 JP	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	2006-554156	15-Feb-2005		Board of Regents, The University of Texas System
G0744.70039KR00	GTC-224 KR	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	10-2006-7019275	15-Feb-2005		Board of Regents, The University of Texas System
G0744.70039US01	GTC-224	METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS	11/057522	14-Feb-2005	US-2005-0192226-A1	Board of Regents, The University of Texas System
G0744.70040US00	GTC-226	METHOD OF USING RECOMBINANT HUMAN ANTITHROMBIN FOR NEUROCOGNITIVE DISORDERS	10/835836	30-Apr-2004	US-2005-0245444-A1	GTC
G0744.70042AT00	GTC-3 AT	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	Genzyme and US Dept. of HHS
G0744.70042BE00	GTC-3 BE	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	Genzyme and US Dept. of HHS
G0744.70042EP00	GTC-3 EP	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	Genzyme and US Dept. of HHS

G0744.70042FR00	GTC-3 FR	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042DE00	GTC-3 DE	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042IT00	GTC-3 IT	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042LU00	GTC-3 LU	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042NL00	GTC-3 NL	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042SE00	GTC-3 SE	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042GB00	GTC-3 GB	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	87303112.4	09-Apr-1987	EP0264166	20-Apr-1988	264166	21-Aug-1996	Genzyme and US Dept. of HHS
G0744.70042US03	GTC-3C2	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	07938322	31-Aug-1992			7045676	16-May-2006	Genzyme
G0744.70042US07	GTC-3 D3	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	07839194	20-Feb-1992					Genzyme
G0744.70042US08	GTC-3 C3	TRANSGENIC ANIMALS SECRETING DESIRED PROTEINS INTO MILK	08246259	19-May-1994			6727405	27-Apr-2004	Genzyme and US Dept. of HHS
G0744.70043IL00	GTC-206 IL	METHOD FOR CONTINUOUS, AUTOMATED BLENDING OF SOLUTIONS FROM ACIDS AND BASES	168619	18-Nov-2003					Taurus ISA LLC (joint venture of GTC and Fresenius)
G0744.70044AU00	GTC-28 AU	SUBUNIT OPTIMIZED FUSION PROTEINS	200138831	18-Sep-2000	781462	17-Apr-2001	781462	15-Sep-2005	GTC
G0744.70044NZ00	GTC-28 NZ	SUBUNIT OPTIMIZED FUSION PROTEINS	517774	18-Sep-2000	1507	28-Jan-2005	517774	12-May-2005	GTC
G0744.70045AU00	GTC-238 AU	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	2006304886	23-Oct-2006					GTC and Genzyme
G0744.70045CA00	GTC-238 CA	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	2626542	23-Oct-2006					GTC and Genzyme
G0744.70045CN00	GTC-238 CN	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	200680048006.X	23-Oct-2006					GTC and Genzyme

G0744.70045EP00	GTC-238 EP	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	6844220.1	23-Oct-2006	1945666	23-Jul-2008	GTC and Genzyme
G0744.70045IL00	GTC-238 IL	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	191095	23-Oct-2006			GTC and Genzyme
G0744.70045JP00	GTC-238 JP	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	2008-536622	23-Oct-2006			GTC and Genzyme
G0744.70045KR00	GTC-238 KR	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	10-2008-7012185	23-Oct-2006			GTC and Genzyme
G0744.70045NZ00	GTC-238 NZ	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	568433	23-Oct-2006			GTC and Genzyme
G0744.70045US01	GTC-238	ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE	11/586431	23-Oct-2006	US-2008- 0118501-A1	22-May-08	GTC and Genzyme
G0744.70046AU00	GTC-225 AU	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	2005227064	08-Feb-2005			GTC
G0744.70046CA00	GTC-225 CA	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	2560930	08-Feb-2005			GTC
G0744.70046CN00	GTC-225 CN	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	200580013810.X	08-Feb-2005	CN101027080 A	29-Aug-2007	GTC
G0744.70046EP00	GTC-225 EP	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	5713340.7	08-Feb-2005	1732587	20-Dec-2006	GTC

G0744.70046IL00	GTC-225 IL	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	177877	08-Feb-2005	GTC
G0744.70046JP00	GTC-225 JP	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	2007-501797	08-Feb-2005	GTC
G0744.70046KR00	GTC-225 KR	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	10-2006-7020867	08-Feb-2005	GTC
G0744.70046US01	GTC-225 01	METHODS OF PROTEIN FRACTIONATION USING HIGH PERFORMANCE TANGENTIAL FLOW FILTRATION	11/051216	04-Feb-2005 US-2005- 0197496-A1	GTC
G0744.70047AU00	GTC-10 AU	TRANSGENICALLY PRODUCED ANTITHROMBIN III	5026296	21-Feb-1996	GTC
G0744.70047CA00	GTC-10 CA	TRANSGENICALLY PRODUCED ANTITHROMBIN III	2197675	21-Feb-1996	GTC
G0744.70047US00	GTC-10	TRANSGENICALLY PRODUCED ANTITHROMBIN III	08/391743	21-Feb-1995	GTC
G0744.70047US01	GTC-10C	TRANSGENICALLY PRODUCED ANTITHROMBIN III	09/143155	28-Aug-1998	GTC
G0744.70047US02	GTC-10C2	TRANSGENICALLY PRODUCED ANTITHROMBIN III	10/188658	02-Jul-2002	GTC
G0744.70047US03	GTC-10C3	TRANSGENICALLY PRODUCED ANTITHROMBIN III	11/284585	14-Nov-2005	Ovation
G0744.70048WO00	GTC-239 PCT	INTRAPERITONEAL ADMINISTRATION OF ANTITHROMBIN III, RELATED COMPOSITIONS AND METHODS	PCT/US2007/0039 77	14-Feb-2007	Academic Medical Center, Department of Surgery
G0744.70049AU00	GTC-241 AU	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	2003249247	14-Jul-2003	Mayo Foundation for Medical Education and Research
G0744.70049CA00	GTC-241 CA	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	2492561	14-Jul-2003	Mayo Foundation for Medical Education and Research
G0744.70049CN00	GTC-241 CN	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	3821906.9	14-Jul-2003	Mayo Foundation for Medical Education and Research
			1688603A	26-Oct-2005	

G0744.70049EP00	GTC-241 EP	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	3764649.4	14-Jul-2003	1543034	22-Jun-2005	Mayo Foundation for Medical Education and Research
G0744.70049NZ00	GTC-241 NZ	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	538216	14-Jul-2003		26-Sep-08	Mayo Foundation for Medical Education and Research
G0744.70049US02	GTC-241	TREATMENT AND PROPHYLAXIS WITH 4- 1BB-BINDING AGENTS	12769462				Mayo Foundation for Medical Education and Research
G0744.70050EP00	GTC-242 EP	ENHANCEMENT OF IMMUNE RESPONSES BY 4-1BB-BINDING AGENTS	2802551.8	09-Oct-2002	EP1434596	07-Jul-2004	Mayo Foundation for Medical Education and Research
G0744.70050US01	GTC-242	ENHANCEMENT OF IMMUNE RESPONSES BY 4-1BB-BINDING AGENTS	10492056	17-Aug-2004	US-2005- 0013811-A1	20-Jan-2005	Mayo Foundation for Medical Education and Research
G0744.70051US01	GTC-243	METHODS AND PRODUCTS RELATED TO THE TRANSFER OF MOLECULES FROM BLOOD TO THE MAMMARY GLAND	11788775	20-Apr-2007	US-2008- 0063780-A1	13-Mar-08	GTC
G0744.70058AU00	GTC-13 AU	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	29402797	13-May-1997		05-Dec-1997	GTC
G0744.70058AT00	GTC-13 AT	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058BE00	GTC-13 BE	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058CA00	GTC-13 CA	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	2254871	13-May-1997		25-Mar-08	GTC
G0744.70058DK00	GTC-13 DK	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058EP00	GTC-13 EP	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058FI00	GTC-13 FI	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058FR00	GTC-13 FR	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058DE00	GTC-13 DE	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC
G0744.70058GR00	GTC-13 GR	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	GTC

G0744.70058IE00	GTC-13 IE	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058IT00	GTC-13 IT	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058JP00	GTC-13 JP	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	09-541036	13-May-1997					GTC
G0744.70058LU00	GTC-13 LI	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058LU00	GTC-13 LU	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058MC00	GTC-13 MC	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058NL00	GTC-13 NL	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058NZ00	GTC-13 NZ	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	332916	13-May-1997			332916	07-Sep-2000	GTC
G0744.70058PT00	GTC-13 PT	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058ES00	GTC-13 ES	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058SE00	GTC-13 SE	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058CH00	GTC-13 CH	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058GB00	GTC-13 GB	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	97923643.7	13-May-1997	EP09233308	20-Nov-1997	923308	18-Sep-2002	GTC
G0744.70058US00	GTC-13	PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES FROM MILK	08/648235	13-May-1996			6268487	31-Jul-2001	GTC
G0744.70059AU00	GTC-30 AU	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	2000-2432	14-Apr-2000			781915	06-Oct-2005	GTC
G0744.70059BE00	GTC-30 BE	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059DE00	GTC-30 DE	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059EP00	GTC-30 EP	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059FR00	GTC-30 FR	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059GB00	GTC-30 GB	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059IE00	GTC-30 IE	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059NL00	GTC-30 NL	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	922208.4	14-Apr-2000	EP1181351	27-Feb-2002	1181351	12-Nov-2008	GTC
G0744.70059NZ00	GTC-30 NZ	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	514792	14-Apr-2000	1496	27-Feb-2004	514792	08-Jun-2004	GTC

G0744.70059US01	GTC-30	METHOD OF PURIFYING HETEROLOGOUS PROTEINS	09/550001	14-Apr-2000				GTC
G0744.70061US01	GTC-29 D	METHODS AND VECTORS FOR IMPROVING NUCLEIC ACID EXPRESSION	11/403633	13-Apr-2006	US-2006-0179500-A1	10-Aug-2006		GTC
G0744.70063US02	GTC-14D	TRANSGENICALLY PRODUCED PROLACTIN	09/490657	24-Jan-2000			6545198	GTC
G0744.70079AT00	GTC-52AT	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079EP00	GTC-52	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079FR00	GTC-52FR	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079DE00	GTC-52DE	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	59405566	GTC
G0744.70079IT00	GTC-52IT	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079J00	GTC-52	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079CH00	GTC-52CH	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Apr-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079GB00	GTC-52GB	METHOD FOR STERILIZING MILK BY FILTRATION	94111744.2	28-Jul-1994	EP0638242	15-Feb-1995	638242	GTC
G0744.70079US00	GTC-52	PROCESS FOR STERILE FILTRATION OF MILK	08/282256	29-Jul-1994			5576040	GTC
G0744.70080US01	GTC-63C	INHIBITOR-RESISTANT UROKINASE	07/942157	08-Sep-1992				TSI Corp. (wholly owned subsidiary of GTC)
G0744.70081US00	GTC-33C	METHODS OF RECONSTRUCTED GOAT EMBRYO TRANSFER	09/298971	23-Apr-1999			6580017	GTC